Get started
Author

Loïck Vidot

Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer
2023 · Gerald W. Prager, Julien Taieb, et al. · New England Journal of Medicine · 506
Effect of trifluridine/tipiracil in patients treated in RECOURSE by prognostic factors at baseline: an exploratory analysis
2020 · Josep Tabernero, Guillem Argiles, et al. · ESMO Open · 58
PDF
Safety, efficacy and patient-reported outcomes with trifluridine/tipiracil in pretreated metastatic colorectal cancer: results of the PRECONNECT study
2020 · Jean-Baptiste Bachet, Lucjan Wyrwicz, et al. · ESMO Open · 45
PDF
Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: final results from the phase IIIb single-arm PRECONNECT study by duration of therapy
2023 · Julien Taieb, Timothy Price, et al. · BMC Cancer · 13
PDF
Exploratory analysis of the effect of FTD/TPI in patients treated in RECOURSE by prognostic factors.
2019 · Josep Tabernero, Alberto F. Sobrero, et al. · Journal of Clinical Oncology · 9
Futility Interim Analysis Based on Probability of Success Using a Surrogate Endpoint
2024 · Ronan Fougeray, Loïck Vidot, et al. · Pharmaceutical Statistics · 5
PDF
Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: PRECONNECT Turkey
2022 · Ahmet Özet, Faysal Dane, et al. · Future Oncology · 5
Health-related quality of life in the early-access phase IIIb study of trifluridine/tipiracil in pretreated metastatic colorectal cancer (mCRC): Results from PRECONNECT study.
2019 · Julien Taieb, Timothy Jay Price, et al. · Journal of Clinical Oncology · 5
Correction: STK11 and KEAP1 mutations as prognostic biomarkers in an observational real-world lung adenocarcinoma cohort
2020 · Timothy Price, Chiara Cremolini, et al. · ESMO Open · 4
Clinical and quality of life outcomes with trifluridine/tipiracil: PRECONNECT and TALLISUR studies
2023 · Lucjan Wyrwicz, Julien Taieb, et al. · Colorectal Cancer · 2
SO-18 Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: Final results according to duration of treatment from the phase IIIb, international, open-label, early-access PRECONNECT study
2021 · J. Taieb, T. Price, et al. · Annals of Oncology · 2
PDF
Brazilian cohort results of the PRECONNECT study: safety and efficacy of trifluridine/tipiracil in metastatic colorectal cancer
2022 · Celso Abdon Lopes de Mello, Felipe Melo Cruz, et al. · Brazilian Journal of Oncology · 1
PDF
SO-18 Reinforcing clinical outcomes with patient-reported QoL outcomes in patients with mCRC receiving FTD/TPI: Pooled analysis of PRECONNECT and TALLISUR studies
2022 · L. Wyrwicz, J. Taieb, et al. · Annals of Oncology · 1
PDF
Pcn49 Indirect Comparison of Hrqol Data for Patients With Treatment-refractory Metastatic Colorectal Cancer Treated With Trifluridine & Tipiracil (preconnect Trial) Compared With Bsc & Regorafenib (correct Trial)
2019 · S. Moreno, M. Greenwood, et al. · Value in Health · 1
PDF
Exploratory analysis of the effect of FTD/TPI in mCRC patients treated in RECOURSE by different prognostic factors: impact on ECOG PS
2019 · G. Argiles, J. Tabernero, et al. · Annals of Oncology · 1
Works count: 17
Citation count: 658
H-index: 5
I10-index: 4
Year
Topic
Type